Chromane Derivatives

Abstract

This invention relates to compounds of the formula (I):

Description

Claims

1-10. (canceled)

11. A compound of the formula (I):

12. The compound or the pharmaceutically acceptable salt, as claimed in claim 11, wherein: R1 is a hydroxy group, C1-C6 alkoxy group or C1-C6 alkyl-carbonyl-oxy group; andR3 and R4 are independently a C1-C6 alkyl group or a C3-C7 cycloalkyl group, said C1-C6 alkyl group and said C3-C7cycloalkyl group being unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a halogen atom, a hydroxy group, a C1-C6 alkoxy group and a C3-C7 cycloalkyl group, or R3 and R4 taken together with the nitrogen atom to which they are attached form an azetidinyl group, a pyrrolidinyl group, a morpholino group or a homomorpholino group, said azetidinyl group, said pyrrolidinyl group, said morpholino group and said homomorpholino group being unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a hydroxy group, a C1-C6 alkyl group, a C1-C6 alkoxy group and a hydroxy-C1-C6 alkyl group.

13. The compound or the pharmaceutically acceptable salt, as claimed in claim 11, wherein: -A-B— is —CH2—O—;R1 is a hydroxy group;R2, R3 and R4 are independently a C1-C6 alkyl group;R5 and R7 are independently a hydrogen atom, a halogen atom or a C1-C6 alkyl group; andR6 and R8 are independently a hydrogen atom or a halogen atom.

14. A compound selected from: (S)-(−)-3-(Hydroxymethyl )-N,N,2-trimethyl-8-[(5-methyl-3,4-dihydro-2H-chromen-4-yl)amino]imidazo[1,2-a]pyridine-6-carboxamide;(+)-8-(3,4-Dihydro-2H-chromen-4-ylamino)-3-(hydroxymethyl)-N,N,2-trimethylimidazo[1,2-a]pyridine-6-carboxamide;(S)-(−)-8-[(5,7-Difluoro-3,4-dihydro-2H-chromen4-yl)amino]-3-(hydroxymethyl)-N,N,2-trimethylimidazo[1,2-a]pyridine-6-carboxamide; and(−)-8-[(5-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-3-(hydroxymethyl)-N,N,2-trimethylimidazo[1,2-a]pyridine-6-carboxamide;or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 11, and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 14, and a pharmaceutically acceptable carrier.

17. The pharmaceutical composition of claim 16 further comprising other pharmacologically active agent(s).

18. A method of treating a condition mediated by acid pump inhibitory activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof, as claimed in claim 14.

19. A method of treating gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, cancer, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof, as claimed in claim 14.

20. A method of treating gastroesophageal reflux disease (GERD) comprising administering to a mammal in need of such treatment a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof, as claimed in claim 14.